These findings are in keeping with those of Tanei et al., who reported that in 108 patients with locally advanced breast cancer, treated with taxane/anthracyline-based NAC, ALDH1(+) tumors were significantly associated with low pCR rates [26]. Here, ALDH1A1 is linked to breast carcinoma.